Patents by Inventor Bruce E. Maryanoff

Bruce E. Maryanoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10092620
    Abstract: The present invention provides cyclic compounds that are useful in preventing or treating atherosclerosis or related disorders. The invention also provides therapeutic methods for treating or preventing various diseases or disorders associated with or mediated by atherosclerosis. Further provided in the invention are methods of screening for anti-atherosclerotic cyclic peptides with improved properties.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: October 9, 2018
    Assignee: The Scripps Research Institute
    Inventors: M. Reza Ghadiri, Luke J. Leman, Yannan Zhao, Bruce E. Maryanoff
  • Publication number: 20160250280
    Abstract: The present invention provides cyclic compounds that are useful in preventing or treating atherosclerosis or related disorders. The invention also provides therapeutic methods for treating or preventing various diseases or disorders associated with or mediated by atherosclerosis. Further provided in the invention are methods of screening for anti-atherosclerotic cyclic peptides with improved properties.
    Type: Application
    Filed: April 2, 2014
    Publication date: September 1, 2016
    Inventors: M. Reza GHADIRI, Luke J. LEMAN, Yannan ZHAO, Bruce E. MARYANOFF
  • Patent number: 9079896
    Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters and prodrugs thereof, pharmaceutical compositions containing compounds of formula (I) and the use of said compounds and compositions as urotensin II receptor antagonists.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: July 14, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: William A. Kinney, Diane K. Luci, Bruce E. Maryanoff, Shyamali Ghosh, Edward C. Lawson
  • Patent number: 8853263
    Abstract: The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative and a therapeutically effective amount of one or more anticonvulsant and/or anti-epileptic agents.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: October 7, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Virginia L. Smith-Swintosky, David F. McComsey, Michael H. Parker, Allen B. Reitz, Bruce E. Maryanoff
  • Patent number: 8759342
    Abstract: The invention is directed to benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one Urotensin II receptor antagonists useful in treating or ameliorating a Urotensin-II mediated disorder. More specifically, the present invention relates to certain novel benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one compounds and methods for preparing compounds, compositions, intermediates and derivatives thereof. Pharmaceutical compositions and methods for treating or ameliorating a Urotensin-II mediated disorder using compounds of the invention are also described.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: June 24, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ghosh Shyamali, William A Kinney, Edward C Lawson, Diane K Luci, Bruce E Maryanoff, Francois Maria Sommen
  • Patent number: 8680278
    Abstract: The present invention is directed to a process for enantioselectively preparing substituted piperidine alkanoic acid integrin antagonist compounds.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: March 25, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: William A. Kinney, Christopher A. Teleha, Shyamali Ghosh, Bruce E. Maryanoff, Gabriela Grasa, Antonio Zanotti-Gerosa, Jonathan Alan Medlock
  • Patent number: 8546358
    Abstract: The present invention is directed to a method for treating or ameliorating asthma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of compound 17:
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: October 1, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael J. Hawkins, Michael N. Greco, Eugene Powell, Lawrence de Garavilla, Bruce E. Maryanoff
  • Patent number: 8536189
    Abstract: The present invention is directed to a compound of Formula (I): or a form thereof, wherein X1, X2, X3, X4, R1, R2 and R3 are as defined herein, useful as tryptase inhibitors.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 17, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael J. Costanzo, Stephen C. Yabut, Brett Tounge, Bruce E. Maryanoff, Han-Cheng Zhang
  • Patent number: 8536174
    Abstract: The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: September 17, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bruce E. Maryanoff, William A. Kinney, Edward C. Lawson, Diane K. Luci, Shyamali Ghosh
  • Publication number: 20120214817
    Abstract: The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.
    Type: Application
    Filed: April 30, 2012
    Publication date: August 23, 2012
    Inventors: Bruce E Maryanoff, William A. Kinney, Edward C. Lawson, Diane K. Luci, Nikolay Marchenko, Sergey Sviridov, Shyamali Ghosh
  • Publication number: 20120165327
    Abstract: The present invention is directed to a compound of Formula (I): or a form thereof, wherein X1, X2, X3, X4, R1, R2 and R3 are as defined herein, useful as tryptase inhibitors.
    Type: Application
    Filed: March 1, 2012
    Publication date: June 28, 2012
    Inventors: Michael J. Costanzo, Stephen C. Yabut, Brett Tounge, Bruce E. Maryanoff, Han-Cheng Zhang
  • Patent number: 8193191
    Abstract: The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: June 5, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Bruce E. Maryanoff, William A. Kinney, Edward C. Lawson, Diane K. Luci, Shyamali Ghosh
  • Patent number: 8158792
    Abstract: The present invention is directed to a compound of Formula (I): or a form thereof, wherein X1, X2, X3, X4, R1, R2 and R3 are as defined herein, useful as tryptase inhibitors.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: April 17, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Michael J. Costanzo, Stephen C. Yabut, Brett Tounge, Bruce E. Maryanoff, Han-Cheng Zhang
  • Patent number: 8148385
    Abstract: The present invention is directed to novel bicyclic triazolopyrimidine compounds of Formula (I) or a form thereof: wherein X1, X2, R1, R2, R3 and R4 are as defined herein, and their methods of preparation and use as ADP inhibitors.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: April 3, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Hong Ye, Cailin Chen
  • Patent number: 8110683
    Abstract: The invention is directed to piperidinyl compounds that selectively bind integrin receptors and methods for treating an integrin mediated disorder.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: February 7, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Bart De Corte, William A. Kinney, Bruce E. Maryanoff, Shyamali Ghosh, Li Liu
  • Publication number: 20120022022
    Abstract: The present invention is directed to a compound of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof, and methods for treating inflammatory and serine protease mediated disorders.
    Type: Application
    Filed: September 26, 2011
    Publication date: January 26, 2012
    Inventors: Michael J. Hawkins, Michael N. Greco, Eugene Powell, Lawrence de Garavilla, Bruce E. Maryanoff
  • Patent number: 8084490
    Abstract: The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: December 27, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: David F. McComsey, Michael H. Parker, Allen B. Reitz, Bruce E. Maryanoff
  • Patent number: 8076294
    Abstract: The present invention relates to a collagen-related polypeptide (CRP) having hydrophobic amino acid groups at the N- and C-termini capable of non-covalent self-assembly into collagen mimetic triple helices and fibrils thereof and the synthesis, methods of use and compositions thereof.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: December 13, 2011
    Assignee: Advanced Technologies and Regenerative Medicine, LLC.
    Inventors: William A. Kinney, Mabel Alarnino Cejas, Bruce E. Maryanoff, Thomas Matalenas, Chunlin Yang
  • Publication number: 20110136824
    Abstract: The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.
    Type: Application
    Filed: February 14, 2011
    Publication date: June 9, 2011
    Inventors: Bruce E. Maryanoff, William A. Kinney, Edward C. Lawson, Diane K. Luci, Nikolay Marchenko, Sergey Sviridov, Shyamali Ghosh
  • Patent number: 7915260
    Abstract: The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: March 29, 2011
    Inventors: Bruce E. Maryanoff, William A. Kinney, Edward C. Lawson, Diane K. Luci, Nikolay Marchenko, Sergey Sviridov, Shyamali Ghosh